Access Biotechnology helped the small molecule drug developer increase its total funding to over $300m in a round led by BVF Partners.
US-based small molecule drug developer Nimbus Therapeutics completed a $105m funding round yesterday backed by conglomerate Access Industries’ life sciences investment subsidiary, Access Biotechnology.
Investment partnership BVF Partners led the round, which included RA Capital Management, Atlas Venture, Commodore Capital, Logos Capital, Surveyor Capital and an unnamed alternative asset manager. It increased the company’s total funding to more than $300m.
Nimbus is developing a range of small molecule compounds that have demonstrated the potential to treat prevalent health conditions such…
